The Foundayo sleep apnea trials found fewer breathing interruptions after a year of treatment. That is encouraging, but the pill is not approved to treat sleep apnea. The main analysis found about 12 to 13 fewer events an hour beyond placebo, a treatment without the active drug. The findings also aren't permission to stop prescribed airway treatment.
Foundayo sleep apnea results: what happened
As of November 12, 2026, the day this article was written, ATTAIN-OSA results published November 9 in JAMA describe two 52-week trials. They tested orforglipron, sold as Foundayo, against placebo. Lilly funded the studies.
Foundayo acts on GLP-1, a gut hormone signal involved in appetite and blood sugar. It is a daily pill, with a different active ingredient from semaglutide or tirzepatide. The general Foundayo guide covers that broader comparison.
Obstructive sleep apnea, or OSA, means the upper airway repeatedly narrows or closes during sleep. The trials measured AHI, the apnea-hypopnea index: breathing pauses or shallow breaths per hour of sleep.
One trial enrolled 363 adults who weren't using positive airway pressure, or PAP, a machine that holds the airway open. The other enrolled 349 adults already using PAP.
The JAMA abstract reports these changes at one year:
| Change in breathing events per hour | PAP nonusers | Existing PAP users |
|---|---|---|
| Foundayo | −17.8 | −17.3 |
| Placebo | −4.5 | −5.3 |
| Additional decrease versus placebo | −13.2 | −12.0 |
The differences are reported as published; subtracting rounded numbers can give a slightly different result.
What this means alongside Zepbound
A pill could add another option for people whose sleep apnea and excess weight overlap. It has not yet gained a sleep-apnea indication, meaning an authorized use on its label.
Zepbound, the branded tirzepatide product, already has that indication. The FDA's December 20, 2024 decision covers moderate-to-severe OSA in adults with obesity, alongside reduced-calorie eating and increased physical activity.
The 2024 SURMOUNT-OSA paper in the New England Journal of Medicine tested tirzepatide separately. Neither program assigned people directly to Foundayo versus Zepbound, so their numbers cannot establish which works better.
Our guide to tirzepatide for sleep apnea explains the branded indication. The SURMOUNT-OSA results guide covers its trial numbers. That indication does not extend to compounded tirzepatide.
Why Lilly's headline numbers look different
Lilly's November 9 release reports decreases of 21.1 events an hour without PAP and 18.3 with PAP. Those are changes within the Foundayo groups. A placebo-adjusted difference subtracts the change in the placebo group from the change in the medicine group.
There is a second distinction. An estimand is the exact treatment question a statistical analysis tries to answer. The paper's main “treatment regimen” analysis accounts for treatment stops. Lilly's “efficacy” analysis estimates what would happen if everyone remained on assigned treatment without specified additional treatments.
In Lilly's analysis, the AHI decreases were 43.8% without PAP and 27.5% with PAP. Starting averages were 50.7 and 57.6 events an hour. These are separately modeled estimates, so the percentages aren't calculated by simply dividing the displayed averages.
The same release reports weight decreases of 11.5% and 11.2%, respectively. Those figures belong to its continued-treatment analysis too.
About three in ten Foundayo participants without PAP, 31.5%, reached its combined target of remission or mild disease. That meant fewer than 5 breathing events an hour, or 5 to fewer than 15 without excessive daytime sleepiness. It did not mean everyone had stopped having sleep apnea.
What it means for someone prescribed semaglutide
This result doesn't supply a breathing-benefit estimate for semaglutide. Foundayo contains a different molecule. Sharing a hormone pathway doesn't make two medicines interchangeable.
Weight management and treating blocked breathing are related goals, but they aren't the same measurement. A change on the scale cannot tell a clinician how many breathing interruptions remain.
The semaglutide and sleep apnea guide separates those questions. An existing semaglutide prescription still needs its own review of goals, side effects and other medicines; ATTAIN-OSA doesn't decide whether a switch makes sense.
What the results don't mean for CPAP
CPAP is a type of PAP that supplies steady air pressure through a mask. The American Heart Association's November 9 study report says researchers emphasized that this medicine isn't meant to replace CPAP.
Participants using PAP continued it during the study, except for a seven-day pause before sleep testing. That was a measurement step, not a plan for stopping treatment at home. Changes to prescribed airway treatment belong with the sleep clinician and reassessment of breathing.
The report also notes that people with diabetes, mild OSA or a body-mass index below 27 were excluded. Body-mass index compares weight with height. The results don't settle treatment for those groups or outcomes beyond one year.
Side effects still belong in the conversation
The JAMA abstract reports stomach and bowel problems in about seven in ten Foundayo participants: 68.0% and 70.6% across the trials. Placebo rates were 37.4% and 36.6%.
Lilly's release identifies nausea, diarrhea, constipation, indigestion and vomiting as common problems, generally mild to moderate. Health problems led 12.2% and 6.8% of Foundayo participants to stop treatment, compared with 3.8% and 0.6% on placebo.
As of November 12, 2026, the day this article was written, the FDA's November 9 safety communication requires eye-warning information for this drug class, including Foundayo. It concerns NAION, a rare loss of blood flow to the optic nerve, which carries signals from the eye to the brain. It can cause permanent vision loss. For sudden painless vision loss, blind spots, color changes or blurred patches, FDA says to contact a health care professional right away.
What it means for a compounded prescription
Compounded means a licensed pharmacy prepares a medication for an individual prescription. Tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Neither preparation was tested in ATTAIN-OSA.
A licensed provider may still prescribe — that decision is between you and your doctor.
What to watch next
Foundayo's FDA label, marked “Revised: 07/2026,” covers adult weight management, not sleep apnea. Lilly says it plans to submit the sleep-apnea results to FDA by the end of 2026. A planned submission is not a decision.
The useful next milestones are the submission, the agency's decision and any resulting label. Those will show whether the new use is authorized and whom it covers.
Promise does not offer orforglipron. At Promise, a licensed U.S. provider reviews every request and prescribes only when medically appropriate. Not everyone qualifies.





